HealthX Connect Osaka 2026

1 Jul 2026 | Osaka, Japan

Register
Register
Register

Iktos SA

Company (SME/startup) / 中小企業・スタートアップ

iktos.ai/65 rue de Prony, 75017 PARIS, France
8 profile visits

About

Founded in 2016, Iktos is a global leader in artificial intelligence and robotics for drug discovery. Its generative AI technology designs molecules in silico, optimized to meet all the success criteria of a discovery project. Through software and strategic collaborations with pharmaceutical companies, Iktos combines AI-driven molecular design with robotic synthesis and biological testing to accelerate drug discovery. With over 60 successful projects to date, Iktos is also advancing its own pipeline of drug candidates in oncology, obesity and metabolism, inflammatory and autoimmune diseases. The company completed a €15.5M Series A financing round in 2023, co-led by M Ventures and Debiopharm Innovation, with participation from Omnes Capital. In 2024, Iktos acquired Synsight, strengthening its platform with cutting-edge cellular imaging and high-content biological screening capabilities. In 2025, Iktos was awarded a €2.5M grant from the European Innovation Council (EIC) Accelerator, with potential follow-on funding of €5M, to advance its integrated AI and robotics platform.

For more information, visit Iktos.ai.

Business Type / 業種

R&D / 研究開発IT Solution / IT、情報技術

Business Domain / 分野

Information technology / ITPharmaceuticals / 医薬品

Disease Area/疾患領域

Oncology/がんNeurology & Psychiatry/中枢神経、精神疾患Infectious diseases /感染症Immunology/免疫・炎症Metabolic diseases /代謝Musculoskeletal System / 筋骨格系Cardiovascular / 循環器Gastroenterology/消化器Dermatology and sensory system/皮膚・感覚器Rare diseases / 希少疾患

Technologies / 技術

AI・Data analysis / AI・データ分析Pharmacological/Safety evaluation / 薬効・薬理・安全性評価Chemical synthesis/化学品合成

Additional Information

Requested business parter / ご希望のビジネスパートナー 

Pharmaceuticals / 医薬品

Representatives

VP, APAC Business Development and Operations

Iktos SA